Why are artemisinin-based combination therapies (ACTs) used for falciparum malaria, and what is the major concern regarding their use?

• A. They are cheap and widely available; no resistance concerns
• B. They target liver stages only; minimal side effects
• C. They provide rapid parasite clearance and reduce resistance development; concern: emergence of artemisinin resistance; need for partner drug to prevent resistance
• D. They are effective for all Plasmodium species equally

Answer: (C)

Artemisinin-based combination therapies are used because they combine a fast-acting artemisinin component with a longer-acting partner drug, giving rapid reduction of parasite biomass and a lower chance of resistance developing. The artemisinin derivative rapidly clears most of the circulating parasites, which helps relieve symptoms quickly, but its short half-life means residual parasites can rebound if treatment is used alone. The partner drug stays in the body longer, finishing the job and reducing the window in which parasites could develop resistance, so the combination both clears infection quickly and helps deter resistance.

The major concern is the emergence of resistance to artemisinins themselves, which has been observed in some regions. That’s why pairing with a partner drug is essential to maintain efficacy and delay resistance. (Liver-stage activity and equal effectiveness across all Plasmodium species aren’t the primary reasons for ACT use in falciparum malaria.)